These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 12115582)

  • 1. Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
    Van Hattum AH; Schlüper HM; Hausheer FH; Pinedo HM; Boven E
    Int J Cancer; 2002 Jul; 100(1):22-9. PubMed ID: 12115582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
    Van Hattum AH; Pinedo HM; Schlüper HM; Hausheer FH; Boven E
    Int J Cancer; 2000 Oct; 88(2):260-6. PubMed ID: 11004678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
    van Hattum AH; Hoogsteen IJ; Schlüper HM; Maliepaard M; Scheffer GL; Scheper RJ; Kohlhagen G; Pommier Y; Pinedo HM; Boven E
    Br J Cancer; 2002 Sep; 87(6):665-72. PubMed ID: 12237778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
    Maliepaard M; van Gastelen MA; Tohgo A; Hausheer FH; van Waardenburg RC; de Jong LA; Pluim D; Beijnen JH; Schellens JH
    Clin Cancer Res; 2001 Apr; 7(4):935-41. PubMed ID: 11309344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer.
    van Hattum AH; Pinedo HM; Schlüper HM; Erkelens CA; Tohgo A; Boven E
    Biochem Pharmacol; 2002 Oct; 64(8):1267-77. PubMed ID: 12234607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
    Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
    Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
    Maliepaard M; van Gastelen MA; de Jong LA; Pluim D; van Waardenburg RC; Ruevekamp-Helmers MC; Floot BG; Schellens JH
    Cancer Res; 1999 Sep; 59(18):4559-63. PubMed ID: 10493507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
    Schellens JH; Maliepaard M; Scheper RJ; Scheffer GL; Jonker JW; Smit JW; Beijnen JH; Schinkel AH
    Ann N Y Acad Sci; 2000; 922():188-94. PubMed ID: 11193894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
    Perego P; De Cesare M; De Isabella P; Carenini N; Beggiolin G; Pezzoni G; Palumbo M; Tartaglia L; Pratesi G; Pisano C; Carminati P; Scheffer GL; Zunino F
    Cancer Res; 2001 Aug; 61(16):6034-7. PubMed ID: 11507048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
    Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
    Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350.
    Yin MB; Hapke G; Wu J; Azrak RG; Frank C; Wrzosek C; Rustum YM
    Biochem Biophys Res Commun; 2002 Jul; 295(2):435-44. PubMed ID: 12150968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
    Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
    Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.
    Scheffer GL; Maliepaard M; Pijnenborg AC; van Gastelen MA; de Jong MC; Schroeijers AB; van der Kolk DM; Allen JD; Ross DD; van der Valk P; Dalton WS; Schellens JH; Scheper RJ
    Cancer Res; 2000 May; 60(10):2589-93. PubMed ID: 10825126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins.
    Petrangolini G; Supino R; Pratesi G; Dal Bo L; Tortoreto M; Croce AC; Misiano P; Belfiore P; Farina C; Zunino F
    J Pharmacol Exp Ther; 2006 Sep; 318(3):939-46. PubMed ID: 16714402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
    Rajendra R; Gounder MK; Saleem A; Schellens JH; Ross DD; Bates SE; Sinko P; Rubin EH
    Cancer Res; 2003 Jun; 63(12):3228-33. PubMed ID: 12810652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antisense oligonucleotide reverses topotecan-resistant ovarian cancer cells].
    Jia P; Wu SB; Xu Q; Wu MF; Gao QL; Liao GN; Lu YP; Ma D
    Ai Zheng; 2003 Dec; 22(12):1296-300. PubMed ID: 14693055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.